Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR DISOPROXIL FUMARATE.
EMTRIVA vs TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Nucleotide reverse transcriptase inhibitor; tenofovir diphosphate competitively inhibits HIV-1 and HBV reverse transcriptase and incorporates into viral DNA causing chain termination.
Emtricitabine 200 mg orally once daily.
300 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Terminal elimination half-life: ~17 hours in HIV-infected patients; prolonged to ~28 hours in renal impairment (CrCl <50 mL/min).
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Renal: ~70-80% unchanged via glomerular filtration and active tubular secretion; minimal biliary/fecal (<1% as unchanged drug).
Category C
Category A/B
Antiretroviral, NRTI
NRTI